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Abstract Worseningof underlyingbronchospasmmaybe associatedwith acute exacerbations of chronicobstructive
pulmonarydisease (COPD).As airwayobstructionbecomesmore severe, thetherapeuticoptionis to adda short-acting
inhaled b2-agonist as needed to cause rapid relief of bronchospasm.Unfortunately, however, themost e¡ective dosage
may increase above that recommended during acute exacerbations.Formoterol (Oxis1) Turbuhaler1has a rapid onset
of action (withinminutes) anddemonstrates amaintainede¡ectonairway function.Inthis study,weexaminedthee¡ects
of formoterol used as needed in 20 patients with acute exacerbations of COPD. A dose^response curve to inhaled
formoterol (9 mgper inhalation) orplacebowas constructedusing three separate inhalations, i.e. a total cumulative dose
of 27 mg. Dose increments were given at 20-min intervals, with measurements being made 15min after each dose.
Formoterol, but not placebo, induced a large and signi¢cant (P50?001) dose-dependent increase in forced expiratory
volume in1sec (FEV1) [mean di¡erences frombaseline = 0?1311after 9 mg formoterol (95% Cl: 0?096^0?167)] 0?1811after
18 mg formoterol (95% Cl: 0?140^0?2221) and 0?2081 after 27 mg formoterol (95% Cl: 0?153^0?2631). However, 27 mg
formoterol did not induce further bene¢t [0?0271 (95% Cl: 70?008^0?0621); P= 0?121] when compared with 18 mg
formoterol.Results of this study suggest the use of higher than customary dose of formoterol for as-needed therapy to
provide rapid relief of bronchospasm in patients su¡ering from acute exacerbations of partially reversible COPD.
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Acute exacerbations of chronic obstructive pulmonary
disease (COPD)mayresult in deterioration of theunder-
lying bronchospasm. This worsened air£ow obstruction
maybe reversed in somepatients by the use of broncho-
dilators (1). Although the amount of reversibility
achievedmaybe relatively small, any improvement in air-
£ow could be extremely important in the management
of these patients (2).
For increased airway obstruction, the therapeutic
option is to add a short-acting inhaled b2-agonist, such
as salbutamol or terbutaline, for rapid relief of broncho-
spasm (3,4). A small number of studies suggest that
inhaled b2-agonists, as a class, are of bene¢t in exacer-
bations of COPD, showing improvements in forced ex-Received11June 2001, accepted in revised form 28 June 2001and
published online 24 September 2001.
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mcazzola@qubisoft.itpiratory volume in 1sec (FEV1) and in dyspnoea scores
(5). Substantial incremental increase in FEV1 in response
to increasing doses of b-agonists beyond those com-
monly used in clinical practice is restricted to a minority
of patients (6), however, the maximal e¡ective dose of
short-acting, inhaledb2-agonists in COPDexacerbations
is not known.The optimal dosagemight be greater than
the conventional one (7).
Barclay et al. (8) have demonstrated that several
COPD patients were not responsive to 200mg inhaled
salbutamol, but they obtained some degree of broncho-
dilation when the dose of inhaled salbutamol was gradu-
ally increased. Other studies have reported similar
¢ndings (9,10).Data from studies of COPD exacerbations
indicate that 3^4 pu¡s of b2-agonists produce signi¢cant
(18^22%) levels of bronchodilation (11,12). Lloberes
et al. (12) showed that, in at least half of the patients,
the dose of salbutamol that produced the maximal
bronchodilation was twice that currently employed.The
functional duration of e¡ect of short-acting inhaled
b2-agonists is decreased in COPD exacerbation (13).
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should be titrated to maximal e¡ect whenever possible
(14).Thus, if 3^4 pu¡s every 4h have not been e¡ective,
short-acting inhaled b2-agonists should be administered
by 3^4 pu¡s every 1^2h, if tolerated, until clinical im-
provement occurs. The American Thoracic Society
(ATS) recommendation for severe COPD exacerbation
is 6^8 pu¡s every 2h (4). Generally, the maximum
bronchodilator response to inhaledb2-agonists in COPD
occurs signi¢cantly later to that observed in asthmatics;
however, it is possible to obtain 80% of the maximum
bronchodilator response quite rapidly (15).
b2-agonists with long-lasting e¡ects (formoterol and
salmeterol) have also been developed and o¡er an inter-
esting new therapeutic option for COPD. However, at
present, their role in COPD treatment is still being de-
bated (16).
Formoterol has been shown to produce dose-propor-
tionalbronchodilation in patientswith partially reversible
obstructive airway disease (17): the onset of action of
formoterol is as rapid asboth salbutamol and terbutaline
(18,19), and a signi¢cant e¡ect occurs with formoterol
within minutes of inhalation of a therapeutic dose (20).
Formoterol administered to patients with moderate
asthma at di¡erent single doses (delivered doses of 4?5,
9, 18 or 27mg), via a speci¢c device (Turbuhaler1),
induced at least a 50% increase in speci¢c airways con-
ductance (sGaw)within1^4min (21).Formoterol induces
a prolonged bronchodilation (approximately 12h) in par-
tially reversible severe COPD (17,22) and, administered
via Turbuhaler1, it causes long-lasting improvements in
lung function in apparently poorly reversible COPD (23).
In consideration of the fast onset of action exhibited
by formoterol, we have investigated the acute broncho-
dilating e¡ect of cumulative doses of this drug adminis-
tered via Turbuhaler1 in patients with acute
exacerbations of COPD to determine if this drug might
be used for as-needed therapy in this condition.
METHODS
Study design
This was a randomized, double-blind, cross-over study
taking place over two consecutive days. All work was
conducted according to the rules of the Declaration of
Helsinki and was approved by an independent scienti¢c
ethics committee.
Patients
Patients attending outpatient clinics with acute exacer-
bation of COPD, and who were willing to participate,
were recruited. The diagnosis of COPD was consistent
with the diagnostic standards of BritishThoracic Society
(BTS) guidelines for the management of COPD (24).Acute exacerbation was de¢ned as a sustained worsen-
ing of the patient’s condition from the stable state and
beyond normal day-to-day variations: that is, acute in
onset and necessitating a change in regular medication
in a patient with underlying COPD (25). All patients had
no indication for hospitalization, according to the BTS
guidelines (24). The protocol of this study included a
placebo treatment. For this reason, due to ethical rea-
sons, all patients were su¡ering from only a mild, acute
exacerbation of COPD. Exacerbations were de¢ned as
mild because each patient had an increased need for
medication, which he/she was able to manage in his/her
own normal environment (25). Table 1 outlines the
baseline characteristics of the population studied.
A bronchodilator response prior to entry into the
study wasnotrequired.Patientswith a historyof asthma,
allergic rhinitis, atopy, or with a total blood eosinophil
countover 400mm73 were excluded.Patientswere also
excluded if they had co-morbidities (such as congestive
heart failure or pulmonary embolus) or complications of
COPD (e.g. pneumothorax) as the aetiology of exacer-
bation of their symptoms.No patientwas su¡ering from
febrile tracheobronchitis.
Additionalmedication
Oral bronchodilators were not permitted during the
study. Inhaled short-acting bronchodilator drugs, and
other inhaled long-acting bronchodilator agents, were
notpermitted for at least12h and 24hprior to each test,
respectively. Short-acting b2-agonists were permitted
soon after each testwhenrequired. All patients received
a treatmentwith anoral antibiotic (co-amoxiclavor levo-
£oxacin) and an inhaled steroid (budesonide 400mg
twice daily).
Patients were asked not to consume cola drinks,
co¡ee or tea and not to smoke in the hours before and
during the investigation.
Treatment
A dose^response curve to formoterol 9mg per inhala-
tion (Oxis, AstraZeneca, Milan, Italy) or placebo, both
administered via Turbuhaler1, was constructed using
three separate inhalations, i.e. a total cumulative deliv-
ered dose of 27mg formoterol. After baseline measure-
ments, dose increments were given at 20-min intervals,
with measurements being made 15min after each dose.
Spirometric testing was performed according to the
procedures described in the ATS1987 update (26).Three
acceptable forced expiratory manoeuvres were per-
formed in order to obtain two reproducible results for
forced vital capacity (FVC) and FEV1. The highest FVC
and FEV1, obtained fromone orotherof thereproducible>
curves, were kept for analysis.
Table 1. Anthropometric data andpulmonary function of patients
Patient Sex Age
(yrs)
Height
(cm)
FEV1
(1)
FEV1
(%
predicted)
FVC
(1)
FVC
(%
predicted)
Anthonisen-
type
exacerbation
1 M 61 164 0?65 23 1?05 30 II
2 M 65 165 0?61 22 1?28 37 II
3 F 54 170 1?40 50 2?01 62 I
4 M 69 181 1?43 43 2?12 50 I
5 M 65 163 1?69 64 2?35 70 I
6 M 67 165 1?53 58 2?00 59 II
7 M 86 165 1?03 49 1?65 57 II
8 M 67 172 1?39 47 1?94 51 I
9 M 71 169 1?69 62 2?31 65 II
10 M 61 160 1?32 50 2?09 64 I
11 M 59 168 1?24 41 1?74 46 II
12 M 62 167 0?51 18 0?90 25 II
13 M 65 164 1?00 37 1?26 37 I
14 M 73 160 1?26 55 1?50 50 II
15 M 63 169 1?08 37 2?12 57 II
16 M 75 185 1?52 46 2?11 48 II
17 M 72 161 0?67 28 1?46 48 II
18 M 55 161 0?48 17 1?27 36 I
19 M 83 176 2?64 61 2?59 71 I
20 M 78 160 0?93 52 1?47 68 II
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Spirometric data for each treatmentwere analysedusing
the Student’s t-test for paired variables. Mean responses
were also compared by multi-factorial analysis of var-
iance (ANOVA) to establish any signi¢cant overall e¡ect
between the two treatments. In thepresence of a signi¢-
cant overall ANOVA, Duncan’s multiple range testing
with 95% con¢dence limits was used to identify where
di¡erences were signi¢cant. A probability level of
P50?05 was considered as signi¢cant for all tests.
RESULTS
Twenty patients were enrolled and all completed the
2-day study. Signi¢cant di¡erences occurred between
the baseline spirometric values of the two treatment
groups for FEV1 [mean di¡erence=0?0471 (95% Cl:
0?006^0?0881); P=0?027], but not for FVC [mean dif-
ference=0?0321 (95% Cl: 70?014^0?0781); P=0?161].
Apparently, no carry-over e¡ect was detectable. In fact,
in the 10 patients who received formoterol as ¢rst and
placebo as second, the mean baseline FEV1 values were
1?2371(95% Cl: 0?940^1?5341) and 1?0671 (95% Cl:
0?816^1?3181), respectively, whereas in the 10 patients
who received placebo as ¢rst and formoteral as second,
the mean baseline FEV1 values were 1?2171 (95% Cl:0?940^1?4941) and 1?141 (95% Cl: 0?860^1?4221),
respectively.
Improvements in FEV1 and FVCwith each cumulative
dose of formoterol were highly signi¢cant compared
with placebo (P=0?001). The mean changes in FEV1 and
FVC from control baseline values for each treatment
are shown in Fig.1.
Formoterol, but not placebo, induced large and signif-
icant (P50?001) dose-dependent increases in FEV1 and
FVC. For FEV1 mean di¡erences from baseline were
0?1311 after 9mg formoterol (95% Cl: 0?096^0?1671),
0?1811 after 18mg formoterol (95% Cl: 0?140^0?2221)
and 0?2081 after 27mg formoterol (95% Cl: 0?153^
0?2631). For FVC, mean di¡erences from baseline were
0?1691 after 9mg formoterol (95% Cl: 0?073^0?2651),
0?2361 after 18mg formoterol (95% Cl: 0?159^0?3131)
and 0?2921 after 27mg formoterol (95% Cl: 0?142^
0?2541). However, 27mg formoterol did not induce
further signi¢cant improvement in FEV1 [0?0271 (95%
Cl: 70?008^0?0621); P=0?121; 0?0571 (95% Cl:
70?031^0?1441); P=0?193] when compared with 18mg
formoterol. It is interesting to note that the mean
percentage increase frombaseline in inspiratorycapacity
(IC), an index of hyperin£ation, after 27mg formoterol
was lower than that in FVC (9?7% and 16?7%,
respectively).
In e¡ect,18mg formoterol induced a higherbronchodi-
lation than did 27mg formoterol in six out of 20 patients,
Fig. 1. Mean (a) FEV1and (b) FVCchanges fromcontrolbaseline values for formoterol (9 mgper inhalation) (&) andplacebo (~).
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sponse evoked by the highest dose of formoterol in
another ¢vepatients. After inhalation of 27mg formoter-
ol Turbuhaler1, 75% of the patients showed an absolute
increase in FEV1of at least160ml.This cut-o¡ for exclud-
ing errors was used due to the known coe⁄cient of
variation of spirometry in patients with COPD (1). After
18mg formoterol, 65% of the patients showed this
increase.
No patient complained of adverse symptoms (e.g. pal-
pitations or signi¢cantly increasedheart rate) during the
study. Moreover, no patient signi¢cantly worsened after
these two days; consequently, no hospital admissionwas
necessary.
DISCUSSION
This study shows that formoterol Turbuhaler1 induces a
rapid and signi¢cant bronchodilation and can be used for
as-needed medication in many patients with acute
exacerbations ofCOPD.Adelivereddose of18mg formo-
terol (24mgmetered dose) seems to induce clinically re-
levant e¡ect in these patients. However, since 70% of
patients examined in this investigation bene¢ted by the
highest used dose of formoterol, it is advisable to admin-
ister a cumulative 27mg delivered dose of formoterol for
as-needed medication. This will cause rapid relief of
bronchospasm in patients with acute exacerbation of
COPD, in agreement with the dose^response relation-
ship found for the increase from baseline in sGaw soon
after inhalation (21).
Although long-acting b2-agonists are currently not
approved for use in exacerbations of COPD and we
know little about their duration of action in this condi-
tion, their long-lastinge¡ect is important.This is particu-
larly truewhen these drugs have a rapid onset of action,
similar to short-acting b2-agonists.These characteristics
might allow for both good relief of symptoms and alsoprolonged control.This means that repeat doses should
not normally be needed.
In this study, formoterolwas administeredviaTurbuha-
ler1. This contrasts with the Veteran Health Adminis-
tration clinical practice guideline for the management of
COPD that strongly encourages use of spacers in COPD
exacerbation (27).The addition of a spacer device, how-
ever, may increase the variability of the available dose
(28).
Toº nnesen et al. (29) demonstrated that inhalation of
terbutaline via Turbuhaler1 produced a signi¢cantly
greater increase in FEV1 compared with the same dose
of the b2-agonist administered via a conventional, chloro-
£uorocarbon inhaler and Nebuhaler1 (750ml spacer) in
patients attending the emergency department with
acute severe bronchial obstruction. Another study
showed that the same bronchodilating e¡ect could be
achieved when half the dose of salbutamol normally gi-
ven via a conventional pressurizedmetered dose inhaler
(pMDI) is given viaTurbuhaler1 in patients with reversi-
ble airway obstruction (30).These ¢ndings are not a sur-
prise because Turbuhaler1 delivers about twice the
amount of drug to the lungs as the pMDI and the
observed di¡erence in deposition is re£ected in the
bronchodilating e¡ect (31). However, some studies
indicate that the dry-powder capsule inhaler and pMDI
formulations of formoterol are equipotent in bronchodi-
lation (18,32).
CONCLUSION
This study suggests the use of higher than customary
dose of formoterol for as-neededmedication in patients
su¡ering from acute exacerbations of partially reversible
COPD. Studies in a larger population will determine if
the functional duration of e¡ect of formoterol is de-
creased in COPD exacerbations, as occurs with short-
acting b2-agonists.
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